novo nordisk a/s-b (NONOF:Grey Market)
Last $174.10 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/13/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for novo nordisk a/s-b (NONOF)
Year over year, Novo Nordisk A/S has been able to grow revenues from kr66.3B DKK to kr78.0B DKK. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 18.97% to 17.26%. This was a driver that led to a bottom line growth from kr17.1B DKK to kr21.4B DKK.
View Income Statement In U.S. Dollar| Currency in Millions of Danish Krones | As of: | Dec 31 2009 DKK | Dec 31 2010 Reclassified DKK | Dec 31 2011 DKK | Dec 31 2012 DKK | 4 Year Trend |
| Revenues | 51,078.0 | 60,776.0 | 66,346.0 | 78,026.0 |  | |
| TOTAL REVENUES | 51,078.0 | 60,776.0 | 66,346.0 | 78,026.0 | | |
| Cost of Goods Sold | 10,438.0 | 11,680.0 | 12,589.0 | 13,465.0 | | |
| GROSS PROFIT | 40,640.0 | 49,096.0 | 53,757.0 | 64,561.0 | | |
| Selling General & Admin Expenses, Total | 18,184.0 | 21,260.0 | 22,249.0 | 24,856.0 | | |
| R&D Expenses | 7,864.0 | 9,602.0 | 9,628.0 | 10,897.0 | | |
| Other Operating Expenses | -341.0 | -657.0 | -494.0 | -666.0 | | |
| OTHER OPERATING EXPENSES, TOTAL | 25,707.0 | 30,205.0 | 31,383.0 | 35,087.0 | | |
| OPERATING INCOME | 14,933.0 | 18,891.0 | 22,374.0 | 29,474.0 | | |
| Interest Expense | -384.0 | -500.0 | -275.0 | -58.0 | | |
| Interest and Investment Income | 313.0 | 235.0 | 274.0 | 124.0 | | |
| Other Non-Operating Expenses, Total | -858.0 | -317.0 | -421.0 | -1,611.0 | | |
| Other Non-Operating Income (Expenses) | -52.0 | 1,667.0 | 1,071.0 | -1,264.0 | | |
| Gain (Loss) on Sale of Investments | -16.0 | -23.0 | -27.0 | -118.0 | | |
| EBT, INCLUDING UNUSUAL ITEMS | 13,988.0 | 18,286.0 | 21,925.0 | 27,811.0 | | |
| Income Tax Expense | 3,220.0 | 3,883.0 | 4,828.0 | 6,379.0 | | |
| Earnings from Continuing Operations | 10,768.0 | 14,403.0 | 17,097.0 | 21,432.0 | | |
| NET INCOME | 10,768.0 | 14,403.0 | 17,097.0 | 21,432.0 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | 10,768.0 | 14,403.0 | 17,097.0 | 21,432.0 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | 10,768.0 | 14,403.0 | 17,097.0 | 21,432.0 | | |
| Recently Viewed | |||
| NONOF:US | $174.10 USD | 0.00 |  |
| Company | Last | Change |
| AstraZeneca PLC | 3,383 GBp | -6.50 |
| Bristol-Myers Squibb Co | $43.30 USD | +0.53 |
| Eli Lilly & Co | $55.90 USD | -0.04 |
| Reckitt Benckiser Group PLC | 4,718 GBp | -25.00 |
| Takeda Pharmaceutical Co Ltd | ¥4,955 JPY | -10.00 |
| View Industry Companies | ||
Industry Analysis
NONOF
Industry Average
| Valuation | NONOF | Industry Range |
| Price/Earnings | 24.2x |
|
| Price/Sales | 6.8x |
|
| Price/Book | 16.1x |
|
| Price/Cash Flow | 19.5x |
|
| TEV/Sales | 5.4x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
